| 2023-12-06 | +0.02 % |
|
| 2023-12-05 | -1.89 % |
|
| 2023-11-28 | +0.3 % |
|
| 2023-11-10 | +0.9 % |
|
| 2023-11-09 | -1.37 % |
|
| 2023-11-03 | +1.96 % |
|
| 2023-11-02 | -0.91 % |
|
| 2023-10-31 | +0.53 % |
|
| 2023-10-30 | +1.35 % |
|
| 2023-10-24 | +1.75 % |
|
| 2023-10-19 | +0.03 % |
|
| 2023-10-11 | -0.84 % |
|
| 2023-10-09 | +0.45 % |
|
| 2023-10-04 | +1.28 % |
|
| 2023-09-29 | -1.21 % |
|
| 2023-09-25 | +0.66 % |
|
| 2023-09-15 | -0.89 % |
|
| 2023-09-11 | -0.24 % |
|
| 2023-09-08 | -0.07 % |
|
| 2023-09-07 | -0.02 % |
|
| 2023-09-05 | -2.51 % |
|
| 2023-08-31 | -2.36 % |
|
| 2023-08-30 | +1.72 % |
|
| 2023-08-28 | +0.04 % |
- Quest Diagnostics (DGX) stock went up by 0.04% last night, but the article does not provide any specific reasons for the increase.
- Quest Diagnostics (DGX) stock went up last night because of the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to the board of directors of Biomerica, Inc., a global biomedical company that develops gastroenterology solutions. Mr. Kenny's industry insights and experience in the medical diagnostic industry are expected to benefit Biomerica and its groundbreaking product, inFoods® IBS, which has the potential to improve the lives of individuals with Irritable Bowel Syndrome (IBS) and capture the interest of larger multinational diagnostic companies.
- The article announces that Invitae, a medical genetics company, has appointed Robert Guigley as its chief commercial officer, which has led to a 0.04% increase in Quest Diagnostics (DGX) stock.
|
| 2023-08-25 | -0.62 % |
|
| 2023-08-21 | -0.46 % |
|
| 2023-08-14 | +0.11 % |
|
| 2023-08-09 | +0.31 % |
|
| 2023-08-04 | -0.76 % |
|
| 2023-08-02 | +0.12 % |
|
| 2023-08-01 | -0.45 % |
|
| 2023-07-31 | +0.54 % |
|
| 2023-07-27 | -1.38 % |
|
| 2023-07-19 | +1.95 % |
|
| 2023-07-18 | +0.32 % |
|
| 2023-07-17 | -0.38 % |
|
| 2023-07-11 | +0.38 % |
|
| 2023-07-10 | +0.55 % |
|
| 2023-07-06 | +0.92 % |
|
| 2023-06-21 | +0.45 % |
|
